纳米比亚温得和克医护人员新冠疫苗对实验室确诊SARS-CoV-2感染的有效性
在纳米比亚温得和克两家主要医院医护人员中开展检测阴性设计研究,2021年10月25日至2022年4月25日纳入1201名医护人员。完全接种基础免疫系列者占26.8%,部分接种占5.2%,未接种占61.2%。完全接种的总体疫苗有效性为61.8%(95%CI 9.3-83.9%),所有13份测序基因组均为奥密克戎变异株。
要点
- 完全接种新冠疫苗基础免疫系列的医护人员总体疫苗有效性为61.8%(95%CI 9.3-83.9%)。
- 1201名医护人员中完全接种占26.8%,部分接种占5.2%,未接种占61.2%。
- 93%参与者有SARS-CoV-2抗体,未接种者中90%有抗体;4.8%RT-PCR阳性。
核心结论
- 新冠疫苗在纳米比亚对奥密克戎变异株感染提供了良好保护,即使许多参与者在研究前已有SARS-CoV-2感染。
- 因此,新冠疫苗应接种于医护人员等高风险人群,且不依赖于既往感染史。
研究设计与样本
- 在纳米比亚两家主要收治COVID-19患者的医院医护人员中开展检测阴性设计研究。
- 医护人员定义为18岁以上直接或间接接触患者、符合新冠疫苗接种条件的医院工作人员。
- 2021年10月25日至2022年4月25日面对面标准化问卷调查主动招募的医护人员,共纳入1201名。
- 通过接种卡、疫苗登记系统和/或District Health Information System 2核实疫苗接种状态;开展呼吸道标本RT-PCR检测和血清学检测(Wantai和Platelia-ELISA)。
- 采用多变量logistic回归模型比较RT-PCR阳性和阴性医护人员的疫苗接种状态,调整混杂因素,计算VE=(1-接种比值比)*100%。
主要发现
- 1201名医护人员中,322名(26.8%)完成基础免疫系列全程接种,62名(5.2%)部分接种,735名(61.2%)未接种。
- 1119名(93%)参与者有SARS-CoV-2抗体,包括637名(90%)未接种参与者。
- 58名(4.8%)参与者RT-PCR检测SARS-CoV-2阳性。
- 所有13份测序基因组均检出奥密克戎变异株(11份BA.1.18,2份BA.1)。
- 完全接种的总体疫苗有效性估计为61.8%(95%CI 9.3-83.9%)。
临床怎么用
- 作者结论认为新冠疫苗应接种于医护人员等高风险人群,且不依赖于既往感染史。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: As of 24 October 2021, 128,868 laboratory-confirmed COVID-19 cases and 3550 deaths were reported from Namibia. The national COVID-19 vaccination campaign that started in March 2021 included health workers (HWs) as a priority group. The vaccines most administered were Sinopharm, AstraZeneca, Pfizer-BioNtech, and Janssen. We aimed to measure the effectiveness of COVID-19 vaccines (VE) amongst HWs against laboratory-confirmed SARS-CoV-2 infection in Namibia. METHODS: We conducted a test negative design (TND) amongst HWs from the two main hospitals treating COVID-19 patients. HWs were defined as all hospital staff over 18 years in direct or indirect contact with patients, eligible for COVID-19 vaccination. We interviewed actively recruited HWs with standardized questionnaires in-person from 25/10/2021 to 25/4/2022. The participants had to state their vaccination status, which was verified through vaccination card, vaccine registry and/or District Health Information System 2. RT-PCR testing of respiratory specimens and serological testing (Wantai and Platelia-ELISA) were conducted. We measured VE by comparing the vaccination status between RT-PCR positive and negative HWs using a multivariable logistic regression model, which was adjusted for confounders. We calculated VE = (1-odds ratio of vaccination)*100 %. RESULTS: We included 1201 HWs of which 322 (26.8 %) participants were fully vaccinated with a primary series against COVID-19, 62 (5.2 %) were partially vaccinated and 735 (61.2 %) were not vaccinated. In total, 1119 (93 %) participants had antibodies against SARS-CoV-2 including 637 (90 %) of the unvaccinated participants. Fifty-eight (4.8 %) participants tested RT-PCR positive for SARS-CoV-2. The Omicron variant was detected in all 13 sequenced genomes (11 BA.1.18, 2 BA.1). The estimated overall VE for full vaccination was 61.8 % (95 %-confidence interval, 9.3-83.9 %). CONCLUSIONS: The VE results suggest that COVID-19 vaccines used in Namibia provided good protection from infections with the Omicron variant even if many participants had a SARS-CoV-2 infection before the study. Therefore, COVID-19 vaccines should be administered to risk groups such as HWs independent from previous infections.
引用
- Sikuvi K, Nghitukwa N, Kakehongo N, et al. Effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection amongst health workers, Windhoek, Namibia. Vaccine. 2025. PMID: 40074602. doi:10.1016/j.vaccine.2025.126977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。